SummaryThis study shows how *Hnf1b* inactivation in pancreatic ductal cells leads to chronic pancreatitis, neoplasia, and potentiates pancreatic intraepithelial neoplasia formation. This shows a cause of pancreatitis and identifies Hnf1b as a potential tumor suppressor for pancreatic cancer.

Pancreatitis is a common disorder with significant morbidity and mortality, yet little is known about its pathogenesis, and there is no specific or effective treatment. It is characterized by progressive inflammation, necrosis/apoptosis, fibrosis, loss of acinar tissue and acinar-to-ductal metaplasia (ADM). Chronic pancreatitis increases the risk of pancreatic cancer.[@bib1] Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies in human beings, occurring through the progression of precursor lesions, the best described being pancreatic intraepithelial neoplasia (PanIN). ADM is critical in neoplastic transformation because metaplastic acinar cells can undergo the reprogramming process from ADM to form PanINs.[@bib2], [@bib3] Fibrosis also provides the background for PanIN development.[@bib4]

The major etiologies of pancreatitis are obstruction of the pancreatic duct, usually caused by gallstones, alcohol, and smoking. Pancreatitis also has been associated with genetic factors, including mutations of the *CFTR* gene, as well as *Protease serine 1 (PRSS1), Serine Protease Inhibitor Kazal Type 1 (SPINK1), Chymotrypsin C (CTRC),* and *Claudin 2 (CLDN2) genes*. However, the cause of chronic pancreatitis cannot be identified in approximately 30% of patients.[@bib4]

The exocrine compartment of the pancreas consists of acinar cells that secrete enzymes and an intricate system of epithelial ductal cells that secrete the fluid carrying the digestive enzymes in the gut. Ductal cells comprise centroacinar cells and intercalated intralobular and interlobular ducts, linking the acinar lobules to the main pancreatic duct that drains into the duodenum.[@bib5] In vertebrates, pancreatic duct morphogenesis initiates with the formation of a network of primitive ducts, which matures into a tubular system. A restricted set of transcription factors are involved in ductal cell differentiation such as Sox9 and Hnf1b.[@bib5], [@bib6] Although acinar cells are not ciliated, ductal cells harbor an immotile primary cilium.[@bib7], [@bib8], [@bib9] These microtubule-based organelles projecting from the surface of the pancreatic ductal cells function as chemosensors and mechanosensors, and integrate multiple signaling pathways.[@bib10] Except for duct obstruction and mutations in the *CFTR* gene, duct contribution in acinar cell homeostasis is poorly known and the cellular and molecular mechanisms leading to acinar damage and chronic pancreatitis are poorly understood.

In the present study, we investigate how duct dysfunction may contribute to pancreatitis. We focused on the transcription factor Hnf1b, which presents a very interesting profile. It is first expressed in pancreatic progenitors, then restricted to ductal cells from late embryogenesis such as only few transcription factors, and therefore not expressed in acinar cells.[@bib11], [@bib12], [@bib13] We previously showed that Hnf1b is crucial for duct morphogenesis during embryogenesis.[@bib13] Here, we investigate its role in differentiated ducts after birth. In the postnatal pancreas, acinar cells do not derive from ducts,[@bib12], [@bib14], [@bib15] allowing analysis of the role of Hnf1b in duct function and the consequences on acinar cell homeostasis.

Our data show that Hnf1b has a crucial function in the regulatory network controlling differentiated epithelial ductal cells and maintenance of the primary cilium. Its ductal function is critical to maintain acinar homeostasis because loss of Hnf1b in ductal cells leads to chronic pancreatitis and neoplasia. Thus, *Hnf1b* deficiency causes dysfunction of the exocrine pancreas, providing further insights into the etiology of pancreatitis and a risk factor for tumorigenesis.

Results {#sec1}
=======

Postnatal Inactivation of Hnf1b in Pancreatic Ducts Leads to Loss of Primary Cilia and Cystic Duct Formation {#sec1.1}
------------------------------------------------------------------------------------------------------------

To perform a postnatal conditional inactivation of *Hnf1b* in ductal cells, we generated Sox9-CreER;Hnf1b^fl/fl^;R26R^YFP^ mutants and conditionally inactivated *Hnf1b* during the first 3 days after birth (postnatal day \[P\] P1--P3), further mentioned as *Hnf1b*Δ^duct^ mutants. We analyzed the consequences on pancreata dissected 5 days after the last tamoxifen (TM) injection, at P8. We assessed that *Hnf1b* inactivation in pancreatic ductal cells was efficient by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), showing a 65% decrease in *Hnf1b* expression in mutants ([Figure 1](#fig1){ref-type="fig"}*A*). By immunostaining, we observed nuclear Hnf1b localization in ductal structures in controls ([Figure 1](#fig1){ref-type="fig"}*B* and *C*), whereas Hnf1b was absent from green fluorescent protein (GFP) positive ducts in mutants. Hnf1b protein persisted in only 14% of nonrecombined ducts, negative for GFP ([Figure 1](#fig1){ref-type="fig"}*D*).Figure 1**Ductal deletion of *Hnf1b* leads to loss of primary cilia, increased ductal cell proliferation, dilatation, and alteration of ductal cell polarity at P8.** (*A*) Analysis of *Hnf1b* inactivation efficiency by RT-qPCR. (*B* and *C*) Hnf1b (red) and GFP (green) immunostaining. Hnf1b+ ductal cells are observed in controls and recombination is monitored by GFP+ cells in Sox9-Cre^ER^;Hnf1b^fl/fl^;R26R^YFP/+^ mutant pancreata. (*D*) Quantification of GFP+ recombined ductal cells in Sox9-Cre^ER^;Hnf1b^fl/fl^;R26R^YFP/+^ mutant pancreata. (*E*) RT-qPCR of ductal and cystic-disease genes. (*F* and *G*) Sox9 (green) and acetylated α-tubulin (Ac-Tub, red) immunostaining. (*H* and *I*) Muc1 (green) and Arl13b (red) immunostaining. Mutant ductal epithelial cells stained with Sox9 and Muc1 are devoid of primary cilia, stained for (*G'*) Ac-Tub and (*I'*) Arl13b. (*J*) Quantification of ciliated ductal cells. (*K--M*) GFP and Ac-Tub immunostaining showing primary cilia loss in recombinant ductal cells from (*M'*) dilated and (*L'*) nondilated ducts. (*N* and *O*) Phosphohistone H3 (PHH3, red) and Sox9 (green) immunostaining. (*P* and *Q*) Quantification of ductal Sox9^+^ cell proliferation and quantification of the number Sox9^+^ cells per area. *Arrows* indicate mitotic Sox9^+^ cells. (*R* and *S*) H&E staining. (*T* and *U*) Sox9 (brown) immunohistochemistry. (*V* and *W*) Protein kinase C zeta (green) and β-catenin (red) immunostaining. (*W*) *Asterisk* shows dilated duct with loss of Protein kinase C zeta apical staining. Protein kinase C zeta apical staining is maintained in (*W'*) nondilated duct, but lost in (*W''*) dilated ducts. (*X* and *Y*) Mucin1 (Muc1, green) and β-catenin (β-Cat, red) immunostaining. (*Y* and *Y'*) *Arrows* show disruption of Muc1 staining in parts of mutant dilated ducts. (*Z* and *AA*) Spp1 (red) and amylase (green) immunostaining. Loss of the apical ductal marker Spp1 was observed in mutants (*AA'*). Nuclei are stained with 4′,6-diamidino-2-phenylindole (blue). *Scale bars*: (*B*, *C*, *N*, *O*, and *R--U*) 50 μm; (*X* and *Y*) 30 μm; (*F--I*, *K--M*, *V*, *W*, *Z*, and *AA*) 10 μm. Control, n = 7; mutant, n = 7 for RT-qPCR; and control, n ≥ 3; mutant, n ≥ 3 for immunostainings. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001. mRNA, messenger RNA.

As a transcription factor, Hnf1b controls a network of genes involved in duct morphogenesis during development.[@bib13] To investigate the role of *Hnf1b* in differentiated ducts after birth, we analyzed the expression of genes involved in the maintenance of the primary cilium and in ductal cell integrity and functionality ([Figure 1](#fig1){ref-type="fig"}*E*). In *Hnf1b*Δ^duct^ mutants, we found a significant decrease in expression of cystic disease genes by RT-qPCR, known as direct targets of Hnf1b in renal cells or in pancreatic progenitors.[@bib13], [@bib14], [@bib15], [@bib16], [@bib17] We observed a strong decrease in *Pkhd1*, *Cys1*, *Spp1*, and *Prox1* expression, involved in ciliary maintenance and/or tubular architecture.[@bib18], [@bib19], [@bib20], [@bib21] *Tg737/Ift88* required for ciliogenesis also was down-regulated significantly. By contrast, the expression of the ductal markers *Sox9*, *Hnf6*, and *Ck19* was unchanged compared with controls, showing that ductal cell differentiation is maintained. Moreover, expression of *Cftr* was unaffected in *Hnf1b*Δ^duct^ mutants.

Because we found a specific down-regulation of genes involved in the maintenance of the ductal primary cilium, we examined primary cilia in *Hnf1b*Δ^duct^ mutants. Immunostaining of acetylated α-tubulin, a tubulin modification present on primary cilium axonemes, showed a loss of cilia in ductal cells of *Hnf1b*Δ^duct^ mutants ([Figure 1](#fig1){ref-type="fig"}*F* and *G*). This was confirmed by the absence of Arl13b immunostaining, a cilium-specific membrane protein ([Figure 1](#fig1){ref-type="fig"}*H* and *I*). Quantification showed a 73% decrease in ciliated ductal cells in *Hnf1b*Δ^duct^ mutants ([Figure 1](#fig1){ref-type="fig"}*J*), in agreement with the level of *Hnf1b* inactivation efficiency. To correlate *Hnf1b* inactivation and the loss of the primary cilium at the cellular level, we performed acetylated α-tubulin/GFP co-immunostainings. *Hnf1b-*inactivated ducts labeled with GFP do not present any cilia ([Figure 1](#fig1){ref-type="fig"}*K--M*).

Because loss of cilia may promote aberrant cell division, permitting increased proliferation,[@bib22] we quantified proliferation of ductal cells by Sox9/Phospho-histone H3 (PPH3) immunostainings ([Figure 1](#fig1){ref-type="fig"}*N* and *O*). Mutant ducts presented more proliferative cells than control pancreatic ducts (1.4-fold) ([Figure 1](#fig1){ref-type="fig"}*P*). This resulted in a significant increase of the ductal cell area (1.2-fold), quantified by the number of Sox9+ cells ([Figure 1](#fig1){ref-type="fig"}*Q*).

We investigated if these abnormalities could lead to cyst formation. By H&E staining, we observed dilated ducts in *Hnf1b*Δ^duct^ mutants ([Figure 1](#fig1){ref-type="fig"}*R* and *S*). Sox9 and Hnf6 showed nuclear staining of enlarged mutant ductal structures ([Figure 1](#fig1){ref-type="fig"}*T* and *U*, and data not shown), showing that dilated ducts still express some terminal differentiation markers. We further analyzed ductal cell polarity. Control ducts showed strong apical localization of Muc1 and Protein kinase C zeta in epithelial cells around the duct lumen ([Figure 1](#fig1){ref-type="fig"}*V--Y*). In *Hnf1b*Δ^duct^ mutants, this apical staining persisted in nondilated ducts ([Figure 1](#fig1){ref-type="fig"}*W'*), whereas it was reduced and discontinuous in the cells lining cysts in mutants ([Figure 1](#fig1){ref-type="fig"}*W''*). Although the Spp1/osteopontin matricellular protein was localized on the apical side of control ductal cells, we observed very few Spp1+ cells in mutants, confirming RT-qPCR results ([Figure 1](#fig1){ref-type="fig"}*Z* and *AA*).

Altogether, these results show that Hnf1b has a prominent role in the regulatory network controlling the maintenance of the primary cilium and tubular architecture of pancreatic ducts after birth.

Postnatal Inactivation of Hnf1b in Pancreatic Ducts Leads to Non--Cell Autonomous Effects on Acinar Cells Through Activation of the YAP Mechanotransducer {#sec1.2}
---------------------------------------------------------------------------------------------------------------------------------------------------------

A direct antagonistic interaction between ciliogenesis and YAP function has been shown.[@bib23] YAP activation also was observed in hepatic cystogenesis associated with *Pkhd1* deficiency.[@bib24] YAP has a central role as a mechanoeffector and sensor of cell polarity, being a mediator of mechanical cues and linking the physicality of cells and tissues to potent transcriptional responses. It is mechanically regulated by various regimens of cell stretching, such as deformations of epithelial monolayers.[@bib25], [@bib26], [@bib27] In *Hnf1b*Δ^duct^ mutants, we visualized the deformation of pericystic areas with immunostaining of the fibroblast marker α-smooth muscle actin (α-SMA) at P8. Although α-SMA+ cells were restricted around blood vessels in control pancreata ([Figure 2](#fig2){ref-type="fig"}*A*), mutants displayed widespread α-SMA staining showing activation of fibroblasts surrounding ducts and in periacinar spaces ([Figure 2](#fig2){ref-type="fig"}*A* and *B*). Interestingly, we observed an increased number of cells with YAP nuclear staining in *Hnf1b*Δ^duct^ mutants in pericystic and acinar areas ([Figure 2](#fig2){ref-type="fig"}*C--F*). Consistent with YAP activation, we found a strong increase in YAP transcriptional targets, with up-regulation of *Ctgf* (1.8-fold) and *Lamc2* in *Hnf1b*Δ^duct^ mutants compared with controls ([Figure 2](#fig2){ref-type="fig"}*G*). To determine in which cell type we observed the YAP nuclear enrichment, we performed co-immunostainings for YAP/Sox9 and YAP/amylase to analyze ductal and acinar cells, respectively. Although in controls YAP localized only in the nucleus of Sox9+ ductal cells ([Figure 2](#fig2){ref-type="fig"}*H--M*), in mutants, it also localized ectopically in amylase+ acinar cells ([Figure 2](#fig2){ref-type="fig"}*N--S*), suggesting that mechanical stress induced by enlarging cysts stimulates YAP activation in acinar cells at P8. These data show cell autonomous and non--cell autonomous up-regulation of the YAP pathway when *Hnf1b* is inactivated in ductal cells.Figure 2**Ductal deletion of *Hnf1b* leads to up-regulation of the YAP pathway at P8.** (*A* and *B*) Sox9 (green) and α-SMA (red) immunostaining. α-SMA staining was observed in smooth muscle cells in vessel walls in (*A*) controls, whereas SMA was activated ectopically in periductal cells in (*B*) mutants. (*C* and *D*) YAP (red) and Sox9 (green) immunostaining. (*E* and *F*) YAP (red) and amylase (green) immunostaining. (*D* and *F*) Nuclear YAP immunostaining is localized ectopically in periductal and acinar cells in mutants. (*G*) RT-qPCR analysis of YAP transcriptional targets. (*H--M*) YAP (red) and Sox9 (green) immunostaining. Merged images show YAP/Sox9 colocalization in ductal cells in (*J'*) controls and (*M'*) mutants. (*N--S*) YAP (red) and amylase (green) immunostaining. No YAP/amylase colocalization is present in (*P'*) controls, whereas amylase+ cells show YAP+ nuclear staining in (*S'*) mutants. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). *Scale bars*: (*A--F*) 50 μm; (*H--S*) 20 μm. \*\**P* \< .01. Control, n = 7; mutant, n = 7 for RT-qPCR and control, n ≥ 3; mutant, n ≥ 3 for immunostainings.

Postnatal Inactivation of Hnf1b in Ducts Leads to ADM, Loss of Acinar Cells, and Lipomatosis {#sec1.3}
--------------------------------------------------------------------------------------------

YAP nuclear localization and increased expression of the YAP target gene *Ctgf* is particularly interesting because of its involvement in extracellular matrix fibrosis.[@bib28], [@bib29] Accordingly, we observed a marked increase in periductal collagen deposition as indicated by histologic analysis with Masson's trichrome at P8 ([Figure 3](#fig3){ref-type="fig"}*A* and *B*, green areas). These changes are reminiscent of pancreas fibrosis, which often is associated with ADM. Because it was recently shown that YAP activity is necessary and sufficient for ADM and pancreatitis induction,[@bib30], [@bib31], [@bib32] we examined whether acinar cells were secondarily affected in mutants. Although we found no significant changes in acinar gene expression by RT-qPCR at P8 ([Figure 3](#fig3){ref-type="fig"}*C*), at this stage we already observed a 41% decrease in the number of amylase+ cells ([Figure 3](#fig3){ref-type="fig"}*D*). We found an up-regulation of *EGFR* expression in mutants (1.6-fold), whereas *TGFβ-1* remained unchanged at this stage ([Figure 3](#fig3){ref-type="fig"}*E*), both known to promote ADM.[@bib33], [@bib34], [@bib35] Moreover, amylase/PPH3 immunostaining quantifications showed a 47% decrease in acinar cell proliferation ([Figure 3](#fig3){ref-type="fig"}*F--H*), whereas terminal deoxynucleotidyl transferase--mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay showed a 15.5-fold increase in acinar cell apoptosis ([Figure 3](#fig3){ref-type="fig"}*I--K*) in mutants compared with controls. Hence, a combined reduction in acinar cell proliferation and an increase in apoptosis leads to acinar cell loss. Then, large areas of ADM were observed at P25 in mutants ([Figure 4](#fig4){ref-type="fig"}*A* and *B*), associated with a dramatic decrease in acinar gene expression (89% for amylase) ([Figure 4](#fig4){ref-type="fig"}*I*) and a strong up-regulation of Sox9 (2.2-fold) ([Figure 4](#fig4){ref-type="fig"}*J*). Moreover, Sox9 and Hnf6 were expressed ectopically in some acinar cells in mutants ([Figure 4](#fig4){ref-type="fig"}*E--H*), characterizing ADM.[@bib36] As previously shown in a model of transforming growth factor (TGF)-β--induced ADM,[@bib37] we also found ectopically induced Hnf1b expression in acinar cells at P25 ([Figure 4](#fig4){ref-type="fig"}*C* and *D*). At this stage, ducts were more affected than at P8, as indicated by the complete loss of Muc1 apical staining in mutants ([Figure 4](#fig4){ref-type="fig"}*K* and *L*), which corroborated with the dramatic decrease in *Muc1* transcript levels ([Figure 4](#fig4){ref-type="fig"}*J*). We found a 55% decrease in *Hnf6* expression ([Figure 4](#fig4){ref-type="fig"}*J*), with few Hnf6+ cells remaining in mutant ducts compared with ductal Sox9+ cells ([Figure 4](#fig4){ref-type="fig"}*C--F*), in agreement with our finding that *Hnf6* is a direct target of Hnf1b during pancreas development.[@bib13] By amylase/Pan-cytokeratin co-immunostainings, acinar structures appear closely connected with this ductal network and, more importantly, Pan-cytokeratin co-localized with some amylase+ cells in mutants ([Figure 4](#fig4){ref-type="fig"}*M* and *N*). We noticed sparse areas with fat infiltration only in mutants and identified that these fat-containing cells were adipocytes using the Fabp4 marker ([Figure 4](#fig4){ref-type="fig"}*O* and *P*), fatty replacement of pancreatic parenchyma often is associated with pancreatic fibrosis and pancreatitis.[@bib4] The YAP pathway was up-regulated dramatically in mutants, stronger than at P8: 8.6-fold for *Ctgf*, 6.3-fold for *Lamc2*, and 2.8-fold for *Cyr61* ([Figure 4](#fig4){ref-type="fig"}*Q*). The Notch pathway was shown to be activated during acinar dedifferentiation and to promote ADM.[@bib38] We found up-regulation of most of the Notch components ([Figure 4](#fig4){ref-type="fig"}*R*), and especially a 2.4-fold increase in *Notch2* expression, a receptor confined to ducts by embryonic day (E)15.5.[@bib39] Moreover, we observed a significant increase in *Jag1* expression, which was shown to be up-regulated in expanded ducts of chronic pancreatitis patients.[@bib40] At this stage, we also observed a strong increase (3.6-fold) in *TGF-β1* expression in mutants and a significant increase in *p8/Nupr1* expression ([Figure 4](#fig4){ref-type="fig"}*S*), a transcriptional co-factor expressed only at low levels in normal pancreata but induced in the initial phases of pancreatitis.[@bib41]Figure 3**Ductal deletion of *Hnf1b* induces pancreatic fibrosis and loss of acinar cells by P8.** (*A* and *B*) Masson\'s trichrome staining shows collagen deposition in green in mutants. (*C*) RT-qPCR analysis of acinar markers. (*D*) Number of amylase^+^ cells per area. (E) RT-qPCR of *EGFR* and *TGF-β1*. (*F* and *G*) Phosphohistone H3 (PHH3, red) and amylase (green) immunostaining. *Arrows* indicate mitotic amylase^+^ cells. (*H*) Quantification of acinar cell proliferation (amylase+ PHH3+/amylase+ cells). (*I* and *J*) TUNEL assay (green) and amylase (red) immunostaining. *Arrows* indicate apoptotic amylase^+^ cells. Nuclei are stained with 4′,6-diamidino-2-phenylindole (blue). (*K*) Quantification of acinar cell apoptosis. *Scale bars*: 50 μm. Control, n = 4; mutant, n = 4 for quantification of immunostainings, and control, n = 7; mutant, n = 7 for RT-qPCR. \*\**P* \< .01; \*\*\**P* \< .001.Figure 4**Ductal deletion of *Hnf1b* leads to ADM and lipomatosis at P25.** (*A* and *B*) H&E staining. *Arrows* show acini with increased lumen size in mutants, a feature of ADM. (*C* and *D*) Amylase (green) and Hnf1b (red) immunostaining. (*E* and *F*) Amylase (green) and Sox9 (red) immunostaining. (*G* and *H*) Amylase (green) and Hnf6 (red) immunostaining. *Arrows* show amylase+ cells with nuclear Hnf6+ staining, which is characteristic of ADM in mutants. (*I*) RT-qPCR of acinar markers. (*J*) RT-qPCR of *Hnf6*, *Muc1*, and *Sox9*. (*K* and *L*) Muc1 (green) and β-Cat (red) immunostaining. Muc1 staining is lost at the apical surface of ductal cells in mutants. (*M* and *N*) Amylase (green) and Pan-cytokeratin (red) immunostaining. (*N'*) PanCK localization is expanded in acinar cells of mutants. (*O* and *P*) FABP4 immunostaining shows adipocytes in mutants. (*Q*) RT-qPCR of YAP transcriptional targets (*R*) RT-qPCR of Notch signaling components. (*S*) RT-qPCR of *TGF-β1* and *P8/NuPr1*. *Scale bars*: 50 μm. Nuclei are stained with 4′,6-diamidino-2-phenylindole (blue). Control, n ≥ 3; mutant, n ≥ 3 for immunostainings; and control, n = 7; mutant, n = 8 for RT-qPCR. \**P* \< .05; \*\**P* \< .01; and \*\*\**P* \< .001.

Hence, *Hnf1b* loss of function in ducts leads to loss of acinar cells and ADM, as well as lipomatosis in the pancreas, together with the up-regulation of Yap, Notch, and TGF-β1 pathways.

Postnatal Inactivation of Hnf1b in Ducts Leads to Chronic Pancreatitis in Adults {#sec1.4}
--------------------------------------------------------------------------------

We further investigated the progression in adults of the pancreatic exocrine disorder associated with ductal *Hnf1b* deficiency. We observed a 43% decrease in pancreas weight at 2 months in mutants, whereas mouse weight was unchanged compared with controls ([Figure 5](#fig5){ref-type="fig"}*A*). At 5 months, mouse weight was decreased significantly in mutants as a consequence of pancreatic exocrine deficiency (data not shown)*.* The decreased pancreatic weight was correlated with a dramatic loss of acinar tissue ([Figure 5](#fig5){ref-type="fig"}*B* and *C*), correlated with a 95% decrease in acinar gene expression ([Figure 5](#fig5){ref-type="fig"}*I*). Many lobes of *Hnf1b*Δ^duct^ mutant pancreata were entirely devoid of acinar tissue and merely consisted of isolated ducts embedded within a large mass of fat. Extensive ADM was shown by very few acini scattered in the tissue and showing an enlarged lumen ([Figure 5](#fig5){ref-type="fig"}*E*), duct-like structures ([Figure 6](#fig6){ref-type="fig"}*F*), and a strong Sox9 ectopic localization in acinar cells ([Figure 5](#fig5){ref-type="fig"}*G* and *H*). Mutant pancreata showed inflammation ([Figure 5](#fig5){ref-type="fig"}*J*). We observed a dramatic increase in *F4/80* expression, a marker of macrophages, and in *CD2* expression, a marker of T cells, whereas expression of *CD19*, a marker of B cells, was unchanged ([Figure 5](#fig5){ref-type="fig"}*K*). In correlation, we found up-regulation of CCL2, CCL5, and *CXCL10*, showing the involvement of these chemokines in the mutant inflamed pancreas. Infiltration of macrophages also was observed by F4/80 immunostaining ([Figure 5](#fig5){ref-type="fig"}*L* and *M*), having an important role in the pathogenesis of pancreatitis. Moreover, extensive lipomatosis was observed in mutants ([Figure 5](#fig5){ref-type="fig"}*J*). Fabp4 immunostaining showed extended areas of adipocytes ([Figure 5](#fig5){ref-type="fig"}*N* and *O*), and *PPARγ* expression, a key player in adipocyte differentiation,[@bib42] was increased dramatically (16.6-fold) in mutants ([Figure 6](#fig6){ref-type="fig"}*P*). The pancreatic parenchyma of the mutant was replaced by fibrotic tissue as shown by Masson's trichrome ([Figure 5](#fig5){ref-type="fig"}*Q* and *R*) and a 10.2-fold increase in the expression of the desmoplasia-associated marker *Col1A1* in mutants ([Figure 5](#fig5){ref-type="fig"}*S*). We observed a 12.8-fold increase in *α-SMA* expression in mutants, showing pancreatic stellate cell (PSC) activation, a key mediator in the fibrosis observed in the desmoplastic reaction[@bib43] ([Figure 5](#fig5){ref-type="fig"}*V*). Interestingly, we found a strong accumulation of the mesenchymal-related protein vimentin in mutants ([Figure 5](#fig5){ref-type="fig"}*T* and *U*) correlated with a dramatic increase in *vimentin* expression (47.7-fold) ([Figure 5](#fig5){ref-type="fig"}*V*), as well as up-regulation of another mesenchymal marker, *N-cadherin* (5.5-fold). Inversely, the epithelial marker *E-cadherin* was down-regulated dramatically (87%), showing epithelial-mesenchymal transition (EMT).Figure 5**Ductal deletion of *Hnf1b* leads to chronic pancreatitis at 2 months.** (*A*) Pancreas weight and relative pancreas weight/body weight of 2-month-old mice (control, n = 17; mutant, n = 11). (*B--F*) H&E staining. Mutant pancreata show dramatic loss of (*C*) acinar tissue and (*E* and *F*) ADM. (*G* and *H*) Amylase (green) and Sox9 (red) immunostaining. (*H'*) Nuclear Sox9+ staining in amylase+ cells is characteristic of ADM in mutants. (*I*) RT-qPCR of acinar markers. (*J*) H&E staining shows lymphocyte infiltration and lipomatosis in mutants. (*K*) RT-qPCR of immune infiltrates (*F4/80*, *CD2*, *CD19*), cytokines (*IL10*), and chemokines (*CCL2, CCL5, CXCL10*). (*L* and *M*) Macrophage marker F4/80 (brown) immunostaining. (*N* and *O*) Adipocyte marker Fabp4 (green) immunostaining and (*P*) RT-qPCR of *PPARγ*. (*Q* and *R*) Masson's trichrome staining. (*S*) RT-qPCR of *Col1A1*. (*T* and *U*) Vimentin (brown) immunostaining. (*V*) RT-qPCR of *SMA*, *vimentin* (Vim), *N-Cad*, and *E-Cad*. *Scale bars*: (*B* and *C*) 2 mm; (*D--H*, *J*, *L*, *M*, and *Q--U*) 50 μm; and (*N* and *O*) 100 μm. Nuclei are stained with 4′,6-diamidino-2-phenylindole (blue). Control, n ≥ 3; mutant, n ≥ 3 for immunostaining; and control, n = 8; mutant, n = 5 for RT-qPCR. \*\**P* \< .01; \*\*\**P* \< .001. mRNA, messenger RNA.Figure 6**Ductal deletion of *Hnf1b* leads to enhanced signaling pathways that favor tumorigenesis.** (*A*) RT-qPCR of YAP transcriptional targets. (*B--E*) CTGF (brown) immunohistochemistry. A strong ectopic CTGF staining was observed in (*C'*) acinar cells in mutants in (*D'*) the epithelium of metaplastic ducts and (*E'*) in PanIN. (*F*) RT-qPCR of the Notch pathway. (*G* and *H*) HEY2 immunohistochemistry. (*I*) RT-qPCR of *TGF-β1*. (*J* and *K*) Phospho-SMAD2 (Ser465, Ser467) immunohistochemistry. (*L*) RT-qPCR of *EGFR*. (*M* and *N*) Phospho-AKT (Ser473) immunohistochemistry. Nuclei were counterstained with hematoxylin. *Scale bars*: 100 μm. Control, n ≥ 3; mutant, n ≥ 3 for immunohistochemistry; and control, n = 6; mutant, n = 5 for RT-qPCR. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001.

Thus, inflammation, fibrosis, and activation of PSCs and EMT promote chronic pancreatitis in adult *Hnf1b*Δ^duct^ mutants.

Postnatal Inactivation of Hnf1b in Ducts Leads to Pancreatic Neoplasia and Potentiates Kras^G12V^-Driven PanIN Formation {#sec1.5}
------------------------------------------------------------------------------------------------------------------------

Chronic pancreatitis has been shown to predispose to pancreatic cancer.[@bib1] Activated signaling pathways play a role in ADM and also in early PanIN lesions. We therefore investigated the potential development of PanINs in adult *Hnf1b*Δ^duct^ mutants.

Connective tissue growth factor (CTGF) production is abundant in the desmoplastic stroma present in pancreatic cancer.[@bib44] We found a 4.4-fold increase of *Ctgf* expression in adult *Hnf1b*Δ^duct^ mutants ([Figure 6](#fig6){ref-type="fig"}*A*), and strong ectopic CTGF protein localization in acinar cells in mutants compared with controls ([Figure 6](#fig6){ref-type="fig"}*B* and *C*). Moreover, we observed strong CTGF expression in the epithelium of metaplastic ducts ([Figure 6](#fig6){ref-type="fig"}*D*) and in neoplastic lesions ([Figure 6](#fig6){ref-type="fig"}*E*) in *Hnf1b*Δ^duct^ mutants. *Cyr61* recently was reported to be expressed in PanINs, Cyr61 signaling being critical for EMT and promoting pancreatic carcinogenesis.[@bib45] We found a dramatic increase (6.1-fold) of *Cyr61* in adult *Hnf1b*Δ^duct^ mutants, as well as *Lamc2* and *Birc5*, other markers of the YAP pathway ([Figure 6](#fig6){ref-type="fig"}*A*).

TGF-β pathway activation plays a crucial role in pancreatic tumor initiation through its capacity to induce ADM, providing a favorable environment for neoplasia.[@bib37] We found a 12.8-fold increase in *TGF-β1* expression in mutants compared with controls ([Figure 6](#fig6){ref-type="fig"}*F*), with a 4-fold increase compared with mutants at P25. Moreover, phospho-Smad2 protein was strongly localized ectopically in the nuclei of ADM structures, metaplastic ducts, and fibrotic tissue ([Figure 6](#fig6){ref-type="fig"}*G* and *H*), monitoring the activation of the TGF-β signaling pathway in adult *Hnf1b*Δ^duct^ mutants.

Ectopic Notch activation, promoting both initiation and progression of PanINs, is also an early event in pancreatic carcinogenesis.[@bib46] We found a strong up-regulation of Notch pathway components, higher than at P25, especially for the receptor *Notch2* and the effector *Hey2* (6.4-fold and 5.9-fold, respectively) ([Figure 6](#fig6){ref-type="fig"}*I*). In correlation, Hey2 protein was observed ectopically in acinar cells, in enlarged ducts, and in ADM structures in mutants ([Figure 6](#fig6){ref-type="fig"}*J* and *K*). Aberrant activation of epidermal growth factor receptor (EGFR) signaling is also essential in pancreatic tumorigenesis[@bib34] and we observed a strong up-regulation of *EGFR* (2.3-fold) ([Figure 6](#fig6){ref-type="fig"}*L*) in adult *Hnf1b*Δ^duct^ mutants, along with a strong localization of phospho-AKT in the fibrotic and inflamed tissue of the mutant pancreas ([Figure 6](#fig6){ref-type="fig"}*M* and *N*).

Remarkably, histologic analysis showed intraepithelial neoplasia as low-grade PanINs in *Hnf1b*Δ^duct^ mutant pancreata ([Figure 7](#fig7){ref-type="fig"}*A*). These were characterized by an epithelium composed of tall columnar cells with basally located nuclei with light atypia, a pseudostratified architecture and abundant supranuclear mucin. These neoplastic structures were Alcian blue--positive ([Figure 7](#fig7){ref-type="fig"}*B*) and positive for the PanIN-specific marker claudin 18 ([Figure 7](#fig7){ref-type="fig"}*C*). Thus, loss of *Hnf1b* leads to pancreatic neoplasia by 2 months. By GFP immunostainings, we performed a lineage tracing analysis and found no GFP signal in ADM/PanIN in Hnf1b mutants, strongly suggesting that PanIN-like structures derived indirectly from Hnf1b-ablated YFP+ ductal cells, by a non--cell autonomous mechanism ([Figure 7](#fig7){ref-type="fig"}*D*).Figure 7**Ductal deletion of *Hnf1b* leads to PanIN by 2 months.** (*A*) H&E staining of mutant pancreata showing epithelial structures composed of columnar cells with abundant supranuclear cytoplasm and basally located nuclei. (*B*) Alcian blue staining. Columnar mutant epithelial cells showed blue-stained supranuclear mucin. (*C*) PanIN marker claudin 18 (brown) immunohistochemistry. (*D*) Sox9 (red) and GFP (green) immunostaining. Sox9+ ADM structures did not derive from Hnf1b-targeted GFP+ cells. (*E*) Quantification of the relative surface of acini, adipocytes, fibrosis/infiltrates, ADM, and PanINs in mutants (n = 6). *Scale bars*: 100 μm. Control, n ≥ 3; mutant, n ≥ 3 for histology and immunohistochemistry. DAPI, 4′,6-diamidino-2-phenylindole.

By quantification of the acinar compartment in mutants, 11.6% of remaining acini, 80.8% of adipocytes, 6.1% of fibrosis/infiltrates, 1.3% of ADM, and 0.5% of PanIN were observed in mutants ([Figure 7](#fig7){ref-type="fig"}*E*). By analyzing older animals until 18 months, we did not observe PanIN progression (data not shown). We then investigated if loss of Hnf1b could promote tumorigenesis in the context of oncogenic Kras (Kras^G12V^). Somatic activating mutations in Kras indeed appear in 97% of PDAC patients, but additional factors are required to initiate PanIN progression and PDAC. To activate Kras in acinar cells, we used the Elas-tTA; TetO-Flpase; FRT-Stop-FRT Kras^G12V^ mouse line. Untreated mice (without doxycycline) develop PanIN lesions with long latency, with low-grade PanIN from 5 to 6 months. We crossed these mice, hereafter referred to as *Kras*, with Sox9-CreER;Hnf1b^fl/fl^ mutants to obtain Elas-tTA; TetO-Flpase; FRT-Stop-FRT Kras^G12V^/Sox9-CreER;Hnf1b ^fl/fl^ with TM induction perinatally, hereafter referred to as *Kras;mutants*. Histologic analyses by H&E staining ([Figure 8](#fig8){ref-type="fig"}*A*), Alcian blue staining ([Figure 8](#fig8){ref-type="fig"}*B*), and claudin 18 immunohistochemistry ([Figure 8](#fig8){ref-type="fig"}*C*) at 5 months showed large area of PanINs in Kras;mutants compared with mutants and age-matched Kras, affecting more lobules with a very large amount of lesions. This showed that a combination of Hnf1b deletion with oncogenic KRAS activation enhanced pancreatic damage at 5 months relative to oncogenic KRAS alone. Quantification of Alcian blue--positive lesions showed a dramatic increase in the surface of lesions in mutant;Kras compared with mutants and Kras ([Figure 8](#fig8){ref-type="fig"}*D*), which was the result of a combined increase in the number of lesions ([Figure 8](#fig8){ref-type="fig"}*E*) and in the size of the lesions ([Figure 8](#fig8){ref-type="fig"}*F*) in mutant;Kras. Moreover, we observed increased progression of PanIN lesions up to high grade at 5 months in mutant;Kras ([Figure 8](#fig8){ref-type="fig"}*G--K*). Thus, Hnf1b inactivation in ducts provides a propitious environment for the onset of KRAS^G12D^-induced PanINs.Figure 8**Ductal deletion of *Hnf1b* promotes PanIN progression in a Kras-activated context.** Sox9-Cre^ER^;Hnf1b^fl/fl^ mutants were crossed with Elas-tTA; TetO-Flpase; Kras^G12V^ mice (referred to as *Kras*) to obtain Sox9-Cre^ER^;Hnf1b^fl/fl^;Elas-tTA; TetO-Flpase; Kras^G12V^ (referred to as *mutant;Kras*) that combined perinatal inactivation of Hnf1b in ducts and oncogenic activation of Kras^G12V^ in acinar cells. Analyses of the pancreata were performed at 5 months. (*A*) H&E staining. (*B*) Alcian blue staining. (*C*) Claudin 18 (brown) immunostaining. (*D*) Quantification of the surface of the lesions stained with Alcian blue. (*E*) Quantification of the number of lesions per cm^2^. (*F*) Quantification of the size of the lesions. (*G--K*) High-grade PanINs in mutant;Kras by (*G--J*) H&E staining and (*K*) Alcian Blue staining. Some lesions present marked cytologic and architectural atypia with the formation of branching papillae. Nuclei are enlarged and hyperchromatic with focal nuclear stratification. *Scale bars*: 100 μm. Mutants, n = 5; Kras, n = 4; mutant;Kras, n = 3. \**P* \< .05; \*\*\**P* \< .001.

Adult Inactivation of Hnf1b in Ducts Leads to Impaired Acinar Regeneration After Cerulein-Induced Pancreatitis {#sec1.6}
--------------------------------------------------------------------------------------------------------------

We next tested the hypothesis that *Hnf1b* could be required for maintenance of exocrine homeostasis in the adult. We inactivated *Hnf1b* in adult ductal cells, with TM injections on 6-week-old mice, and observed the consequences on the pancreatic tissue at 9 weeks and 20 weeks. We did not observe changes in the pancreatic weight in these mutants compared with controls ([Figure 9](#fig9){ref-type="fig"}*A* and *C*). Analysis of acinar marker expression by RT-qPCR ([Figure 9](#fig9){ref-type="fig"}*B* and *D*) and H&E staining ([Figure 9](#fig9){ref-type="fig"}*E* and *F*) yielded no overt pancreatic pathology at either time point when *Hnf1b* was inactivated in adult ducts, probably owing to the lower proliferation rate of adult ductal cells compared with postnatal ductal cells.[@bib5] Thus, we investigated if loss of *Hnf1b* in adults would sensitize acinar cells to injury-induced reprogramming because ductal cells are capable of contributing to acinar regeneration.[@bib47], [@bib48] Two weeks after TM in adults, acute pancreatitis was induced by 2 consecutive days of treatment with the secretagogue cerulein, and pancreata were harvested 1 week later (Day \[D\]7). We verified that *Hnf1b* inactivation also was efficient at this stage, and observed a 50% decrease in *Hnf1b* expression in *Hnf1b*Δ^adult\ duct^ mutants ([Figure 10](#fig10){ref-type="fig"}*A*). We followed *amylase* expression by RT-qPCR and found no significant changes between controls and mutants at D0 and D3. *Amylase* expression was decreased dramatically at D3, showing the efficiency of cerulein treatment ([Figure 10](#fig10){ref-type="fig"}*B*). Although controls showed a recovery of *amylase* expression at D7, *Hnf1b*Δ^adult\ duct^ mutants were unable to recover after injury, showing dramatically low levels of *amylase* expression in mutants (99% decrease). Other acinar markers showed the same pattern of expression with critically low levels of *CPA*, *Ptf1a*, *Mist1*, and *Nr5a2* expression in *Hnf1b*Δ^adult\ duct^ mutants compared with controls at D7 ([Figure 10](#fig10){ref-type="fig"}*C*). In mutants, we observed a dramatic increase in *F4/80* and *CD2* expression, whereas expression of the B-cell marker *CD19* was unchanged ([Figure 10](#fig10){ref-type="fig"}*D*), showing increased severity of pancreatitis in mutants with macrophages and T-cell recruitment. We found a tendency but not a significant increase in the messenger RNA level of *CCL2, CCL5*, and *CXCL10* chemokines in mutants at D7, suggesting that the chronic pancreatitis was more established in *Hnf1b* mutants at 5 months after perinatal inactivation ([Figure 5](#fig5){ref-type="fig"}*K*) than in adult *Hnf1b* mutants 7 days after cerulein treatment ([Figure 10](#fig10){ref-type="fig"}*D*). Histologic analysis by H&E and Masson's trichrome staining showed no abnormalities at D0, but ADM and interstitial fibrosis at D3 both in controls and mutants. At D7, although control pancreata were recovered, we observed persistent and strong defects in *Hnf1b*Δ^adult\ duct^ mutant pancreata, characteristic of chronic pancreatitis ([Figure 10](#fig10){ref-type="fig"}*E*). No large amylase+ acinar clusters were detected in *Hnf1b*Δ^adult\ duct^ mutant pancreata in contrast to controls, and co-localization of Sox9 and amylase was observed in almost all acinar cells in *Hnf1b*Δ^adult\ duct^ mutant pancreata ([Figure 10](#fig10){ref-type="fig"}*F* and *G*), showing widespread ADM at D7. Remarkably, we observed abundant persistent metaplastic lesions, fibrosis, and formation of neoplastic lesions, as shown by histology on H&E ([Figure 10](#fig10){ref-type="fig"}*H* and *I*), Alcian blue staining ([Figure 10](#fig10){ref-type="fig"}*J* and K), and by immunohistochemistry with the PanIN-specific marker claudin 18 ([Figure 10](#fig10){ref-type="fig"}*L* and *M*). These results show the requirement of Hnf1b in adult ducts for acinar cell regeneration in the context of tissue injury. Our data further suggest that *Hnf1b* deficiency in adult ductal cells in the context of tissue injury can initiate neoplastic lesions.Figure 9**Adult *Hnf1b* inactivation in ductal cells does not lead to obvious perturbation of acinar homeostasis.** (*A--F*) Tamoxifen was injected in 6-week-old adult mice and analyses were performed at (*A* and *B*) 2 months or (*C--F*) 5 months. (*A*) Mouse weight, pancreas weight, and relative pancreas weight/body weight of 2-month-old mice. (*B*) RT-qPCR of acinar markers at 2 months. (*C*) Mouse weight, pancreas weight, and relative pancreas weight/body weight of 5-month-old mice. (*D*) RT-qPCR of acinar markers at 5 months. (*E* and *F*) H&E staining of the pancreata at 5 months. *Scale bars*: 100 μm. Control, n ≥ 5; mutants, n ≥ 5. \**P* \< .05. CPA, Carboxypeptidase A.Figure 10**Adult Hnf1b inactivation in ductal cells leads to impaired acinar regeneration and neoplasia after cerulein-induced pancreatitis.** (*A*) Analysis of *Hnf1b* inactivation efficiency by RT-qPCR. (*B*) RT-qPCR of *amylase* at D0, D3, and D7. (*C*) RT-qPCR of acinar markers at D7. (*D*) RT-qPCR of inflammatory markers at D7. (*E*) H&E and Masson trichrome staining. (*F* and *G*) Amylase (green) and Sox9 (red) immunostaining showing widespread ADM at D7 in mutants. (*H* and *I*) H&E staining, (*J* and *K*) Alcian blue staining, and (*L* and *M*) claudin 18 (brown) immunostaining showing PanIN in mutants. *Scale bars*: (*E*) 50 μm; (*F--M*) 100 μm. Control, n ≥ 5; mutants, n ≥ 5 for RT-qPCR; and control, n ≥ 3; mutants, n ≥ 3 for histology and immunostainings. ∗*P* \< .05; ∗∗*P* \< .01; ∗∗∗*P* \< .001.

Discussion {#sec2}
==========

We show that *Hnf1b* inactivation in ductal cells after birth causes loss of primary cilia, duct proliferation, and dilatation. This triggers fibrosis, ADM, inflammatory infiltration, lipomatosis, and activation of PSC and EMT, leading to chronic pancreatitis and PanINs.

*Hnf1b* Inactivation in Differentiated Postnatal Pancreatic Ducts Leads to Chronic Pancreatitis {#sec2.1}
-----------------------------------------------------------------------------------------------

Ductal *Hnf1b* inactivation leads to a dramatic decrease in cystic disease--associated gene expression, especially *Pkhd1* and *Cys1*, reinforcing our previous findings that they were direct targets of Hnf1b in pancreatic progenitors at E12.5.[@bib13] *Pkhd1*, *Cys1*, and *Tg737/Ift88* play a role in the structural integrity of cilia. The *Pkhd1* gene encodes fibrocystin, a membrane protein localized to the primary cilium of tubular epithelial cells,[@bib49] and a lack of fibrocystin disrupted ciliogenesis in *Pkhd1*-deficient mice.[@bib50] Interestingly, it recently was reported that novel mutations of *PKHD1* are associated with chronic pancreatitis.[@bib51] The *Cys1* gene product, cystin, also localizes to the primary cilium and stabilizes microtubule assembly.[@bib52] The protein IFT88/polaris is a core component of the intraflagellar transport machinery and is required for the formation of cilia.[@bib53] Primary cilia transduce signals from extracellular stimuli to a cellular response that regulates proliferation, differentiation, transcription, migration, polarity, and tissue morphology.[@bib54] They can play a negative role in epithelial cell proliferation.[@bib55] Mutations affecting cilia development promote a dilated ductal phenotype or cyst formation.[@bib8], [@bib9], [@bib56] In correlation with the loss of primary cilia, we found increased proliferation of ductal cells in *Hnf1b*Δ^duct^ mutant pancreata. Moreover, this leads to duct dilatation and partial loss of apicobasal polarity of epithelial ductal cells. Some *Hnf1b*Δ^duct^ mutant ducts were devoid of primary cilia, although they were not dilated, strongly suggesting that duct dilatation occurs secondary to the loss of primary cilia. Furthermore, Muc1 immunostaining still was observed in some dilated ducts. We observed weaker expression of Muc1 at P25, whereas it was unchanged at P8. This strongly suggests that loss of apicobasal polarity is a consequence of duct dilatation. *Pkhd1* also is involved in the tubulogenesis and/or maintenance of duct-lumen architecture,[@bib49] and its decreased expression likely contributes to duct dilatation in *Hnf1b*Δ^duct^ mutants. Prox1 was down-regulated significantly in *Hnf1b*Δ^duct^ mutants by P8 and it was shown previously that *Prox1* inactivation results in dilated pancreatic ducts and ADM. *Prox1* mutant adult pancreata uncovered features of chronic tissue damage: acinar apoptosis, macrophage infiltration, mild fibrosis, and extensive lipomatosis,[@bib21] suggesting that reduced *Prox1* expression contributes to the phenotype observed in *Hnf1b*Δ^duct^ mutants. Lineage tracing analysis showed that adipocytes of *Prox1* mutant pancreata did not originate from transdifferentiated pancreatic acinar cells,[@bib21] suggesting that this also may be the case for *Hnf1b*Δ^duct^ mutants, and rather caused by fibroblast activation.[@bib4] Dilated ducts also were reported in pancreata devoid of Hnf6.[@bib56], [@bib57] Pancreatitis was observed in *Hnf6* mutant animals,[@bib57] associated with the finding of shorter primary cilia of ductal cells.[@bib58] We observed a decreased expression of *Hnf6* at P25, whereas it was unchanged at P8, showing that loss of Hnf6 can contribute secondarily to the phenotype. Our data further underscore the link between primary cilia and pancreatitis. Defects in cilia have been associated with a spectrum of human diseases collectively called *ciliopathies*.[@bib59] Ductal cysts, polarization defects, dysplasia, and fibrosis of the pancreas have been described in many ciliopathies. The absence of pancreatic cilia during mouse embryogenesis in *Kif3a* mutants or in hypomorphic Tg737 mutants (*Tg737*^*orpk*^) resulted in lesions that resemble those found in patients with pancreatitis or cystic fibrosis.[@bib7], [@bib8], [@bib9] However, the function of ducts and primary cilia in postnatal pancreatic tissue homeostasis was largely unknown. We show here that *Hnf1b* inactivation leads to loss of primary cilia and duct dilatation, Hnf1b being necessary for the expression of *Pkhd1*, *Cys1*, and *Prox1* in pancreatic ducts. Our results are also of particular interest because genes we found down-regulated in *Hnf1b*Δ^duct^ mutant pancreata also are linked to pancreatic neoplasia.[@bib60], [@bib61], [@bib62]

*Hnf1b* Inactivation in Pancreatic Ducts Leads to Neoplasia and Enhances the Ability of Oncogenic KRAS to Promote Precancerous Lesions {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------------

Because cilia have the ability to physically influence the cell cycle and fine-tune signaling cascades, loss of primary cilia may promote tumorigenesis through aberrant signal transduction. Ciliogenesis indeed was found suppressed in tumor cells, including PanINs and PDAC.[@bib63] YAP was shown to promote cell proliferation[@bib64] and we observed an up-regulation of the YAP pathway and an increased proliferation of ductal cells in *Hnf1b*Δ^duct^ mutants. Recent studies have highlighted the role of YAP in the regulation of cell proliferation during postnatal liver growth and cancer pathogenesis, increased YAP activation was associated with hepatic cyst epithelium proliferation in autosomal-recessive polycystic kidney disease.[@bib24] Moreover, YAP functions as a mechanoresponsive transcriptional co-activator.[@bib25], [@bib26], [@bib27] Our data suggest that mechanical stress induced by enlarging cysts stimulates YAP activation in pericystic and acinar cells. Because YAP activity is necessary and sufficient for ADM and pancreatitis induction,[@bib30], [@bib31], [@bib32] YAP constitutes a molecular link between *Hnf1b* deletion in ductal cells and the non--cell-autonomous effects on acinar cells. Moreover, YAP drives fibrosis by activating fibroblasts.[@bib29] YAP transcriptional targets were progressively overexpressed from P8 to the adult stage: *CTGF* and *Lamc2* from P8, *Cyr61* by P25 and *Birc5* in adults. All of them were strongly up-regulated 4- to 10-fold in adults. In correlation, a 4.5-fold increase in *CTGF* expression was observed in human chronic pancreatitis.[@bib65] CTGF is involved in cell adhesion, cell migration, inflammation, pancreatic fibrosis, tumor growth, and metastasis, and it is overexpressed in human pancreatic cancer.[@bib66] Thus, fibrosis likely is caused by increased *CTGF* expression and this fibrotic microenvironment promotes PanINs in *Hnf1b*Δ^duct^ mutant pancreata. Moreover, LAMC2 recently was identified as a new putative pancreatic cancer biomarker.[@bib67] EGFR, promoting ADM and PanINs,[@bib34] also is involved in ADM induction and formation of neoplastic lesions in *Hnf1b*Δ^duct^ mutants because up-regulation of *EGFR* in mutants was observed from P8, with a 2-fold increase in adults. From P25, Notch and TGF-β signaling contribute to ADM, fibrosis, activation of PSCs, and PanIN development in *Hnf1b*Δ^duct^ mutants, with a 2-fold up-regulation at P25 and 6-fold in adults for Notch signaling, a 4-fold up-regulation at P25 and 13-fold in adults for *TGF-β1* in *Hnf1b*Δ^duct^ mutants. The selective dramatic up-regulations of *Notch2* and *Hey2* in *Hnf1b*Δ^duct^ mutants are in accordance with the finding that centroacinar and terminal ductal epithelial cells did not display up-regulation of *Hes1* transcripts, but did show up-regulated expression of *Hey2* consistent with an active Notch pathway.[@bib68] Moreover, *Notch2* is expressed in ductal cells and PanIN lesions and is a central regulator of PanIN progression and malignant transformation.[@bib69] Notch indeed regulates ADM and promotes both initiation and progression of PanINs.[@bib2], [@bib38], [@bib46] Because TGF-β was shown to trigger ADM in acinar cells,[@bib37] it would be interesting to further test the requirement of TGF-β activation to drive ADM in *Hnf1b*Δ^duct^ mutants with the use of TGF-β inhibitors. TGF-β signaling also is pivotal in driving fibrogenesis, for activation of PSC, and for PanIN formation.[@bib44], [@bib70] Thus, activation of the YAP pathway, EGFR pathway, and subsequent up-regulation of the Notch and TGF-β pathways support the non--cell-autonomous effects leading to ADM, PSC activation, fibrosis, and PanINs in *Hnf1b*Δ^duct^ mutants. Furthermore, we observed an increase in both the number and the grade of PanIN lesions in the pancreas of mice combining both perinatal Hnf1b inactivation in ducts and oncogenic Kras activation in mature acinar cells, showing that loss of Hnf1b promotes PanIN formation in a Kras activated context. Thus, the environment resulting from *Hnf1b* inactivation is favorable for Kras^G12V^-dependent carcinogenesis.

Increased risk for neoplastic conversion also has been linked to perturbations in pathways that control tissue regeneration.[@bib71] We examined the role of Hnf1b in adult ducts in the process of tissue injury and regeneration in the cerulein-induced acute pancreatitis model.[@bib72] Remarkably, our findings show that *Hnf1b* inactivation in adult ductal cells is associated with impaired acinar regeneration and chronic inflammation, allowing ADM and PanIN formation in the context of tissue injury in adults. Whether this role is owing to Hnf1b function in terminal ducts or centroacinar cells will require further investigations.

*HNF1B* Role in Etiology and Physiopathology of the Human Diseases Maturity Onset Diabetes of the Young Type 5, Chronic Pancreatitis, and PDAC {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------------------------

*HNF1B* heterozygous mutations are notably associated with maturity onset diabetes of the young type 5 diabetes, pancreas exocrine dysfunction (pancreatitis with reduced fecal elastase concentration in 93% of these cases, fecal fat excretion), and pancreas structural anomalies (atrophy, cysts, calcification).[@bib73] Pancreatitis was surprising to observe because *Hnf1b* is not expressed in acinar cells and it was proposed that this defect might be caused by pancreas hypoplasia. The results of the present study show that pancreatitis associated with *Hnf1b* deficiency is caused by pancreatic duct alteration. Moreover, differences observed from one patient to another might be owing to impaired recovery of the pancreas in adults because our results also show that *Hnf1b* deficiency leads to altered acinar regeneration after injury.

Studies have shown that down-regulation of *HNF1B* is associated with cancer risk, including renal, prostate, ovarian, and colorectal cancers, showing that HNF1B is a marker of these cancers and a potential tumor suppressor.[@bib74], [@bib75], [@bib76], [@bib77], [@bib78] Pancreatic cancer is poorly characterized at genetic and nongenetic levels. Recent analyses have suggested that reduced HNF1B activity also could be an important step in pancreatic tumorigenesis. Mutations in *HNF1B* have been identified as markers of pancreatic cancer risk loci through genome-wide association study analyses.[@bib79], [@bib80], [@bib81] In PDAC tissues and pancreatic cancer cell lines, *HNF1B* was down-regulated compared with normal pancreatic tissues and this loss of expression contributed to disease aggressiveness.[@bib62], [@bib80] Recently, a regulatory network analysis reported that *HNF1B*, among thousand transcription factors, was the top enriched gene expressed in the normal pancreatic tissue compared with the PDAC regulatory network, identifying HNF1B as a master regulator of PDAC and its subtypes.[@bib82] The present study shows that loss of Hnf1b activity can induce pancreatitis, pancreatic neoplasia, and facilitates the onset of Kras^G12V^-induced PanIN. We show here some molecular mechanisms that link *Hnf1b* dysfunction to pancreatic neoplasia and tumorigenesis. Understanding the first steps of pancreatic tumorigenesis is important and may provide new therapeutic strategies aimed at restoring a normal differentiated state. Hnf1b appears to act as a pancreatic tumor suppressor, which is important for the epithelial state maintenance. Hnf6, one downstream target of Hnf1b, also was proposed as a tumor suppressor,[@bib61] suggesting that maintenance of the ductal phenotype could be important in cancer prevention. Defining the molecular mechanisms underlying the initiation of pancreatic cancer is highly relevant for the development of early detection markers and of potentially novel treatments. Insight on the role of Hnf1b in pancreatic cancer development could lead to its use as a biomarker for early detection and prognosis. Reinforcing HNF1B expression may represent a novel therapeutic strategy to improve the survival of patients with PDAC, together with restoring ciliogenesis by pharmacologic means to improve the effectiveness of other curative options. Thus, these new insights offer potential novel therapeutic strategies.

Material and Methods {#sec3}
====================

Mouse Lines {#sec3.1}
-----------

The *Hnf1b* conditional knockout (Hnf1b^tm1Ics^ denoted as Hnf1b^flox/flox^) carrying LoxP sites flanking exon 4^13^ and Sox9-CreER^T214^ lines have been described previously. The R26R^YFP^ line (B6.129X1-Gt\[ROSA\]26Sortm1\[EYFP\]Cos/J) from the Jackson Laboratory (Bar Harbor, ME) was used to assess recombination efficiency. We performed a conditional deletion of *Hnf1b* in pancreatic ducts by crossing the Hnf1b-floxed mouse line with the TM-inducible Sox9-CreER^T2^ line to generate Sox9-Cre^ER^;Hnf1b^fl/fl^ mice, referred to as *mutants*. Hnf1b^fl/+^ or Hnf1b^fl/fl^ mice are referred to as *controls*. Heterozygous Sox9-CreER;Hnf1b^+/fl^ mice showed no phenotype (data not shown). The Elas-tTA; TetO-Flpase; FRT-Stop-FRT Kras^G12V^ line expressed FLP recombinase under the control of the elastase promoter in a tet-off system, allowing selective expression of the KrasG12V oncoprotein in pancreatic acinar cells. Untreated mice developed PanIN lesions with a long latency[@bib83] and were used in crossings with Sox9-CreER;Hnf1b^fl/fl^ mutants with TM induction perinatally to assess if ductal Hnf1b inactivation promotes PanIN progression in concert with Kras activated in acinar cells. Elas-tTA; TetO-Flpase; Kras^G12V^ are referred to as Kras and Sox9-Cre^ER^;Hnf1b^fl/fl^;Elas-tTA; TetO-Flpase; Kras^G12V^ are referred to as mutant;Kras. Animal experiments were conducted in accordance with French and European ethical legal guidelines and the local ethical committee for animal care (Comité d\'Éthique en Expérimentation Animale Charles Darwin no. 5, approval number: 01508).

Tamoxifen Treatment {#sec3.2}
-------------------

TM (T5648; Sigma-Aldrich, Lyon, France) was dissolved at 25 mg/mL in corn oil and administered intraperitoneally to mice at a dose of 7 mg/40 g of mouse. For postnatal inactivation, TM injections were performed on lactating females during 3 consecutive days after birth, with 1 injection per day (P1, P2, P3), allowing pups to receive TM through breast milk. Dissections were performed at P8, P25, 2 months, and 5 months. For adult inactivation, TM was injected during 4 consecutive days, with 1 injection per day, to 6- or 10-week-old mice.

Cerulein Treatment {#sec3.3}
------------------

Two weeks after adult *Hnf1b* inactivation with TM injections of 10-week-old mice, mice were injected with cerulein (C9026; Sigma), a decapeptide analogue of the pancreatic secretagogue cholecystokinin that induces acinar cell death, at a dose corresponding to 75 μg/kg. Cerulein was dissolved at 1 mg/mL in NaCl and administered to mice at 5 μL/g by injections intraperitoneally hourly, 7 times a day, for 2 consecutive days. Pancreata were harvested at 3 different times after the first cerulein injection: just before cerulein injection at D0, when acute pancreatitis was induced at D3, and when the pancreas was almost fully regenerated at D7.

Histology, Immunohistochemistry, and Immunofluorescence {#sec3.4}
-------------------------------------------------------

Dissected pancreata were fixed in 4% formaldehyde overnight and embedded in paraffin. Sections (7-μm thick) were prepared, deparaffinized, and rehydrated for histologic staining. For H&E staining, slides were incubated with Harris solution (HHS16; Sigma) for 1 minute, and in eosin (HT110216; Sigma) for 3 minutes. For Masson's trichrome staining, slides were incubated with Harris for 5 minutes, rinsed with lithium carbonate and water, incubated with Fuchsin-Ponceau for 3 minutes, and then rinsed with acidified water and 1% phosphomolybdic acid. Slides then were stained with 1% light green for 20 minutes and rinsed with acidified water. For Alcian blue staining, slides were incubated with Alcian blue solution (pH 2.5) for 30 minutes, prepared with Alcian blue 8GX (A3157; Sigma) in 3% acetic acid, rinsed with water, and counterstained with Nuclear Fast Red (Sigma-Aldrich) solution for 5 minutes. Slides were dehydrated before mounting.

Sections were processed for immunofluorescence or immunohistochemistry using a previously described protocol.[@bib16] Briefly, epitope retrieval was performed by heating the slides in a microwave in citric acid buffer (10 mmol/L, pH 6). Permeabilization was performed in phosphate-buffered saline (PBS)/Triton X-100 (Sigma-Aldrich) 0.3%, and sections were incubated in blocking solution (10% milk, 1% bovine serum albumin, 0.1% 10× Triton X-100 in PBS 1× or 1.5% horse/goat serum in PBS 1×) before antibody staining. Nuclei were stained with 4′,6-diamidino-2-phenylindole (1/1000; Sigma) in the secondary antibody staining step. For signal amplification, we used a biotinylated anti-rabbit or anti-goat antibody before incubating with streptavidin--Alexa 594 or streptavidin--Alexa 488. Epitope retrieval for CTGF immunohistochemistry was performed by heating slides in a pressure cooker for 15 minutes. Slides then were incubated in 3% H~2~O~2~ before blocking to eliminate endogenous peroxidase activity. For all other immunohistochemistry experiments, slides were incubated in 1% H~2~O~2~/50% methanol solution before blocking to eliminate endogenous peroxidase activity. The Vectastain peroxidase ABC system (Vector, Peterborough, UK) was used for Sox9, F4/80, vimentin, CTGF, Hey2, Phospho-AKT, Phospho-SMAD, and claudin 18 immunostainings. Nuclei were counterstained with hematoxylin. Primary antibodies are listed in [Table 1](#tbl1){ref-type="table"}. Images were acquired using a Zeiss (Marly-le Roi, France) Axio Observer.Z1 microscope with apotome. For histology, immunofluorescence, and immunohistochemistry, at least 2 sections per pancreas and at least 3 different pancreases of each genotype were analyzed.Table 1AntibodiesAntigenHostDilutionManufacturerAmylaseGoat1/50sc-12821; Santa Cruz Biotechnology (Heidelberg, Germany)Acetylated α-tubulinMouse1/300T6793; SigmaAKT-phospho-S473Mouse1/10066444-1-Ig; Proteintech (Manchester, UK)Arl13bMouse1/10075-287; Antibodies, Inc (Davis, CA)β-cateninMouse1/100610153; BD Biosciences (San Jose, CA)Claudin 18Rabbit1/250700178; ThermoFisher ScientificCTGFRabbit1/3000AAS91519C; Antibody Verify (Las Vegas, NV)F4/80Rat1/500123102; BioLegend (San Diego, CA)Fabp4Rabbit1/200ab13979; Abcam (Paris, France)GFPChicken1/400GFP-1020; Aves Labs (Paris, France)Hey2Rabbit1/10010597-1-AP; ProteintechHnf1bRabbit1/50sc-22840; Santa CruzHnf6Guinea pig1/500Frederic Lemaigre\'s laboratoryMuc1Hamster1/100HM-1630-PO; ThermoFisher Scientificα-smooth muscle actinMouse1/50C6198; SigmaPan-cytokeratinMouse1/100C1801; SigmaPhospho-histone H3Mouse1/3009706; Cell Signaling (Danvers, MA)Phospho-SMAD2 (Ser435, Ser 467)Rabbit1/15044-244G; ThermoFisher ScientificProtein kinase C zetaRabbit1/500sc-216; Santa CruzSox9Rabbit1/100AB5535; Millipore (Molsheim, France)SPP1/osteopontinGoat1/100AF808; R&D SystemsVimentinGoat1/100sc-7557; Santa CruzYAPMouse1/50sc-101199; Santa Cruz

Quantification of Recombined GFP+ Ducts, Ciliated Ductal Cells, Duct Area, Proliferation and Apoptosis, and PanINs {#sec3.5}
------------------------------------------------------------------------------------------------------------------

Quantification of GFP+ ducts in mutants was performed with GFP/Hnf1b immunostainings. More than 2500 GFP+ cells and 500 Hnf1b+ cells were counted (n = 3).

Quantification of ciliated ductal cells at P8 was performed by counting Sox9+ cells with the cilium stained with acetylated tubulin. Almost 500 cells were counted for controls and more than 1000 cells were counted for mutants (control, n = 7; mutant, n = 11). Quantifications of Sox9+ and Amylase+ cells at P8 were performed with at least 2 sections per pancreas (control, n = 4; mutant, n = 4). More than 15,000 Sox9+ and 22,000 amylase+ cells were counted for each genotype. The numbers of Sox9+ and amylase+ cells per mm^2^ were obtained by dividing the numbers of Sox9+ and amylase+ cells by the corresponding cross-sectional areas.

Proliferation of ductal and acinar cells was determined by immunolabeling with PPH3 and Sox9 or amylase antibodies, respectively. Positive cells were scored from at least 3 nonoverlapping fields for each section at 10× magnification. The percentages of PPH3-positive cells were calculated by dividing the number of ductal or acinar cells labeled with PPH3 by the total number of cells expressing Sox9 or amylase. Quantification was performed with at least 2 sections per pancreas (control, n = 4; mutant, n = 4).

Acinar cell apoptosis was determined with a TUNEL analysis, performed using an in situ cell death detection kit (Roche Diagnostics, Meylan, France) and followed by amylase immunostaining. Apoptosis was quantified by counting the number of labeled nuclei. The percentage of TUNEL-positive cells was calculated by dividing the number of TUNEL+/amylase+ cells by the total number of amylase+ acinar cells. Quantification was performed with 3 sections per pancreas (control, n = 4; mutant, n = 4). More than 100 TUNEL-stained acinar cells were counted in controls and more than 800 in mutants.

All counting was performed with Adobe Photoshop CS4 (San Jose, CA).

Quantification of the percentage of remaining acini, adipocytes, fibrosis/infiltrates, ADM, and PanIN was performed on histologic sections of mutant pancreata (n = 6) with ImageJ (National Institutes of Health, Bethesda, MD) and Fiji software.

Quantification of the lesion surface in mutant;Kras compared with Kras and mutants was performed by measuring the surface of the lesions positive for Alcian blue divided by the total surface of the pancreatic area in μm^2^. The results are given in percentages. Each image of the most representative section per sample was acquired by a macro-apotome Zeiss Axiozoomer and the surfaces were quantified by Zen software. The total number of lesions was counted on each image acquired by the macro-apotome for each sample and was normalized by the total surface of the pancreatic area. The results are given as the number of lesions per cm^2^. The size of each lesion also was quantified in μm^2^ (mutants, n = 5; Kras, n = 4; mutant;Kras, n = 3).

Values are shown as means + SEM.

RNA Extraction and RT-qPCR {#sec3.6}
--------------------------

Total RNA from adult pancreas was isolated using the RNeasy Mini-kit (Qiagen, Courtaboeuf, France) and reverse-transcribed using the Superscript RT II Kit with random hexamers (Invitrogen, ThermoFisher Scientific, Illkirch, France). qPCR was performed using a SYBR Green master mix (Eurobiogreen QPCR Mix, Hi-ROX; Eurobio, Courtaboeuf, France). Primer sequences are provided in [Table 2](#tbl2){ref-type="table"}. The method of relative quantification was used to calculate expression levels, normalized to cyclophilin A and relative to wild-type complementary DNA from E15.5 pancreata. Values are shown as means + SEM.Table 2qPCR PrimersNameForward sequence (5'-3')Reverse sequence (5'-3')*Amylase*CTGGGTTGATATTGCCAAGGTGCACCTTGTCACCATGTCT*Birc5*CTGATTTGGCCCAGTGTTTTCAGGGGAGTGCTTTCTATGC*Ccl2*AGCTGTAGTTTTTGTCACCAAGCGTGCTGAAGACCTTAGGGCA*Ccl5*CCTCACCATATGGCTCGGACACGACTGCAAGATTGGAGCA*CD2*AGGATTCTGGAGAGGGTCTCATCGCCTCACACTTGAATGGT*CD19*GTCATTGCAAGGTCAGCAGTGGGGTCAGTCATTCGCTTCCT*Ck19*ACCCTCCCGAGATTACAACCTCTGAAGTCATCTGCAGCCA*Col1A1*ACCTCAAGATGTGCCACTCTGCTCTCTCCAAACCAGAC*CPA*CAACCCCTGCTCAGAAACTTACCTGGACTTGACCTCCACTTCAGA*CTGF*GCCAACCGCAAGATCGGAGTGTACGGCCCCATCCAGGCAA*CXCL10*GCTGCCGTCATTTTCTGCTCTCACTGGCCCGTCATC*Cyclophilin A*CAGGTCCTGGCATCTTGTCCTTGCTGGTCTTGCCATTCCT*Cyr61*TCTGTGAAGTGCGTCCTTGTCTGGTTCTGGGGATTTCTTG*Cys1*AGAGGAGCTCATGGCGAGCATTGCCTGTGGCACAGATGCCAAGA*E-Cad*GCAGTCCCGGCTTCAGTTCCGCCGGCCAGTGCATCCTT*EGFR*GCAGGGAGTGCGTGGAGAAATGGTTGTCTGGTCCCCTGCCTGTA*F4/80*CTTTGGCTATGGGCTTCCAGTCGCAAGGAGGACAGAGTTTATCGTG*Hes1*CAAAGACGGCCTCTGAGCACCCTTCGCCTCTTCTCCATGAT*Hey2*AGCGCCCTTGTGAGGAAACGATGTAGCGTGCCCAGGGTAATTG*Hnf1a*GTGTAACTGCACAGGAGGCAAATTCTCACGTGTCCCAAGACCTA*Hnf1b*GGCCTACGACCGGCAAAAGAGGGAGACCCCTCGTTGCAAA*Hnf6*CAAATCACCATCTCCCAGCAGCAGACTCCTCCTCCTGGCATT*IL10*CAGAGCCACATGCTCCTAGATGTCCAGCTGGTCCTTTGTT*Jag1*TGCCCTCCAGGACATAGTGGACTCTCCCCATGGTGATGCA*LAMC2*ATTGGCTCCCAACCCAGCAGAACAGCTGCCATCACCTCGACA*Mist1*TGGGCCTCCAGATCTCACCAACGTCACATGTCAGGTTTCTCTGCT*Muc1*CTCTGGAAGACCCCAGCTCCAACCACGGAGCCTGACCTGAACT*N-Cad*GCTGACCACGCTCACTGCTATCTGCCCATTCACGGGGTCTA*Notch2*CCTGCCAGGTTTTGAAGGGAGGGCAGTCGTCGATATTCCG*Nr5a2*CTGCTGGACTACACGGTTTGCCTGCCTGCTTGCTGATTGC*P8/Nupr1*GAGAAGCTGCTGCCAATACCGTGTGGTGTCTGTGGTCTGG*Pkd1*GCTGCATGCCAGTTCTTTTGTTTTAAAGTGCAGAAGCCCCA*Pkhd1*TGCTCCTCAGGCAGGCAATCGACCTGTACCCTGGGGTGGCTT*PPARg*GATGGAAGACCACTCGCATTAACCATTGGGTCAGCTCTTG*Prox1*CGCAGAAGGACTCTCTTTGTCGATTGGGTGATAGCCCTTCAT*Ptf1a*TTCCTGAAGCACCTTTGACAGAACGGAGTTTCCTGGACAGAGT*Rbpj*GTTTTGGCGAGAGTTTGTGGAAGATTGGAGGCCGCTCACCAAACT*SMA*GACGCTGCTCCAGCTATGTAGTTGGTGATGATGCCGTGT*Sox9*AAGCCGACTCCCCACATTCCTCCGCCCCTCTCGCTTCAGATCAA*Spp1*CCCTCCCGGTGAAAGTGACTGAGCACCAGCCATGTGGCTATAGG*TGF-b1*AGAGGTCACCCGCGTGCTAATGGGCACTGCTTCCCGAATGTC*Vimentin*GGGAGAAATTGCAGGAGGAGATTCCACTTTGCGTTCAAGG

Statistical Analysis {#sec3.7}
--------------------

Statistical significance was determined using the Student *t* test or the nonparametric Mann--Whitney *U* test when appropriate. Statistical analyses were performed with GraphPad Prism 6.0 (GraphPad Software, Inc, La Jolla, CA). Differences were considered significant at a *P* value less than .05 (NS, not significant; \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001).
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